Search

Xenon Pharmaceuticals Inc

Fermé

SecteurSoins de santé

39.04 0.51

Résumé

Variation du prix de l'action

24h

Actuel

Min

37.86

Max

39.35

Chiffres clés

By Trading Economics

Revenu

-8.4M

-111M

BPA

-1.11

Employés

358

EBITDA

420K

-111M

Recommandations

By TipRanks

Recommandations

Achat Fort

Prévisions sur 12 Mois

+83.17% upside

Dividendes

By Acuity

Prochains Résultats

2 nov. 2026

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-2.2B

3.8B

Ouverture précédente

38.53

Clôture précédente

39.04

Sentiment de l'Actualité

By Acuity

75%

25%

295 / 339 Classement par Healthcare

Xenon Pharmaceuticals Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

22 sept. 2026, 20:07 UTC

News

Xenon Pharmaceuticals Inc is advancing slightly higher, following its announcement to present at the TD Cowen Summit on September 23, 2026.

21 sept. 2026, 20:06 UTC

News
Social Media

Xenon Pharmaceuticals shares fell amid analyst target cuts, with Baird lowering its target to $90 and Needham reducing it to $60, while enrollment in trials is paused.

18 sept. 2026, 23:06 UTC

Xenon Pharmaceuticals Inc is up in after-market trading, buoyed by broader market trends despite ongoing concerns over industrial sector weakness and rising Treasury yields.

17 sept. 2026, 23:01 UTC

Social Media
News

Xenon Pharmaceuticals submits a New Drug Application for azetukalner but pauses new patient enrollment in other studies, leading to a significant decline in after-hours trading.

16 sept. 2026, 20:10 UTC

Xenon Pharmaceuticals Inc is advancing modestly in Wednesday's market session, despite earlier pulling back from a session high amid a broadly lower market.

15 sept. 2026, 20:02 UTC

Xenon Pharmaceuticals shares are lower amid broader market declines linked to a significant drop in the NY Empire State Manufacturing Index for September.

14 sept. 2026, 22:01 UTC

Xenon Pharmaceuticals Inc shares are higher in after-market trading, recovering from recent declines despite remaining below the 20-day moving average. No specific news was identified.

11 sept. 2026, 20:08 UTC

Xenon Pharmaceuticals Inc shares are lower, marking six consecutive sessions of declines. Broader market sentiment may be affected by a rise in the Consumer Price Index.

9 sept. 2026, 20:07 UTC

Xenon Pharmaceuticals Inc. shares are lower today, marking the fourth consecutive session of declines, with no specific news identified for the drop.

8 sept. 2026, 20:41 UTC

Xenon Pharmaceuticals Inc shares are lower in after-market hours amid a broader market decline, with no specific company news identified for the drop.

4 sept. 2026, 23:40 UTC

Xenon Pharmaceuticals Inc shares are higher in after-market hours, despite no specific company news, amid broader macroeconomic influences.

1 sept. 2026, 20:09 UTC

News

Xenon Pharmaceuticals shares are lower as negative sentiment follows an insider sale of 7,068 shares by Chief Medical Officer Kenney Christopher John.

31 août 2026, 23:31 UTC

Xenon Pharmaceuticals Inc shares are higher in after-market trading, reflecting an upward move since Monday's close amid broader market expectations for interest rate hikes.

28 août 2026, 20:02 UTC

News

Xenon Pharmaceuticals shares are lower as the company presented Phase 3 data on azetukalner at the European Epilepsy Congress, amid market volatility.

27 août 2026, 20:02 UTC

Social Media
Event
News

Xenon Pharmaceuticals will present Phase 3 X-TOLE2 trial data at an epilepsy meeting. Shares are lower despite recent announcements regarding upcoming presentations.

26 août 2026, 21:51 UTC

News

Xenon Pharmaceuticals will present data on azetukalner at the European Epilepsy Congress in September 2026, contributing to shares moving higher in after-market hours.

24 août 2026, 19:56 UTC

Xenon Pharmaceuticals Inc shares are lower today, reflecting ongoing market weakness. The stock is near the lower end of its one-month range.

21 août 2026, 23:51 UTC

Xenon Pharmaceuticals shares are lower in after-market trading, reflecting challenges in maintaining upward momentum and positioning below the 20-day moving average.

20 août 2026, 22:51 UTC

Shares of Xenon Pharmaceuticals are lower in after-market trading, continuing a trend of three consecutive daily declines and trading below the 20-day moving average.

19 août 2026, 23:01 UTC

Xenon Pharmaceuticals Inc. is higher in after-market trading, rebounding from an initial dip and reflecting strength despite no specific news to explain the movement.

18 août 2026, 19:26 UTC

Xenon Pharmaceuticals is trading higher today, reflecting cumulative gains since Monday, though it remains below its 20-day moving average.

17 août 2026, 23:01 UTC

Xenon Pharmaceuticals Inc. is trading higher in after-market hours, despite no specific news to explain the move. The stock remains below its 20-day moving average.

15 août 2026, 00:01 UTC

Xenon Pharmaceuticals Inc shares are higher in after-market trading, though no specific news was identified to explain the movement.

14 août 2026, 23:01 UTC

Xenon Pharmaceuticals shares are higher in after-market hours, reflecting a modest gain since Friday's close. The stock remains below its 20-day moving average.

13 août 2026, 19:16 UTC

Xenon Pharmaceuticals Inc shares are declining, trading below their 20-day moving average amid broader market support, despite rising initial jobless claims.

12 août 2026, 22:51 UTC

Xenon Pharmaceuticals Inc. shares are lower in after-market trading, reflecting notable volatility and fluctuations since Wednesday's close within the one-month trading range.

11 août 2026, 23:41 UTC

Xenon Pharmaceuticals Inc shares are lower in after-market trading, continuing a decline since Tuesday's close amid broader market weakness and subdued trading activity.

10 août 2026, 23:41 UTC

Xenon Pharmaceuticals Inc shares are higher in after-market hours, despite earlier pulling back from a session high. No specific news was identified for the movement.

7 août 2026, 20:06 UTC

News
Social Media

Xenon Pharmaceuticals shares are lower as RBC cuts the price target to $81.00 and the company reports a larger-than-expected Q2 loss of $110.7 million.

6 août 2026, 19:36 UTC

Xenon Pharmaceuticals Inc. shares are lower today, retracing earlier gains. The stock is trading near the lower end of its one-month range.

Comparaison

Variation de prix

Xenon Pharmaceuticals Inc prévision

Objectif de Prix

By TipRanks

83.17% hausse

Prévisions sur 12 Mois

Moyen 71.417 USD  83.17%

Haut 90 USD

Bas 46 USD

Basé sur 16 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

16 ratings

15

Achat

1

Maintien

0

Vente

Sentiment

By Acuity

295 / 339Classement par Soins de santé

Sentiment de l'Actualité

Très Fortes Indications Baissières

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Inférieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.